Developed by MindRank, an AI-driven pharmaceutical discovery company, this revolutionary drug, named MDR-001, functions by binding to the glucagon-like peptide-1 receptor (GLP-1-R), a widely recognized target for drug development, as reported by the South China Morning Post (SCMP).
MDR-001 operates by binding to the GLP-1-R receptor, prompting the pancreas to release
. This action assists in reducing blood sugar levels and promoting weight loss among individuals struggling with
and Type 2 diabetes.
In a significant milestone, MDR-001 successfully concluded its phase 1 clinical trials in June, demonstrating superior efficacy and safety standards. Building on this success, the drug proceeded to its phase 2 clinical trials in early September, where participants received multiple doses of the medication.
Advertisement
Notably, MDR-001 achieved Investigational New Drug (IND) approval from both the Food and Drug Administration (FDA) and the National Medical Products Administration (NMPA) within an impressive 19-month time frame, a process that traditionally takes three to four years. Jin Xurui, an AI drug discovery scientist at MindRank, expressed the rapid progress, highlighting the role of AI in expediting development (1✔ ✔Trusted Source
Four key questions on the new wave of anti-obesity drugs
Go to source
).MindRank’s AI-Driven Advantages
MindRank’s proprietary AI computing platform, Molecule Pro, and advanced data center played pivotal roles at every stage of drug development. These cutting-edge technologies significantly contributed to the swift advancement of MDR-001 and showcased the potential of AI in revolutionizing pharmaceutical research.
MDR-001 represents China’s foray into the multi-billion-dollar pharmaceutical market, a sector historically dominated by the US pharmaceutical industry. Niu, an industry expert, emphasized that Chinese companies possess distinctive advantages in specific pharmaceutical segments.
Global Collaboration for Health Improvement
While over half of the world’s AI pharmaceutical companies are currently situated in the US, foreign entities maintain only a slight edge in AI drug development, as explained by Niu. In a highly competitive landscape, nations worldwide leverage their unique strengths to collectively address pressing health challenges and enhance human well-being.
In this context, AI-driven breakthroughs like MDR-001 underscore the potential for global collaboration in advancing healthcare solutions. As China joins the ranks of AI innovators in drug development, the collective goal remains constant: to solve real-world problems and enhance human health on a global scale.
Reference :
- Four key questions on the new wave of anti-obesity drugs – (https:www.nature.com/articles/d41586-023-02445-4)
Source: Medindia
